Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 151


Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment.

Zemek RM, De Jong E, Chin WL, Schuster IS, Fear VS, Casey TH, Forbes C, Dart SJ, Leslie C, Zaitouny A, Small M, Boon L, Forrest ARR, Muiri DO, Degli-Esposti MA, Millward MJ, Nowak AK, Lassmann T, Bosco A, Lake RA, Lesterhuis WJ.

Sci Transl Med. 2019 Jul 17;11(501). pii: eaav7816. doi: 10.1126/scitranslmed.aav7816.


Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma.

Tsao A, Nakano T, Nowak AK, Popat S, Scagliotti GV, Heymach J.

Semin Oncol. 2019 Apr;46(2):145-154. doi: 10.1053/j.seminoncol.2019.06.001. Epub 2019 Jun 18. Review.


Evaluation of the psychometric properties and minimally important difference of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM).

Mendoza TR, Williams LA, Keating KN, Siegel J, Elbi C, Nowak AK, Hassan R, Cuffel B, Cleeland CS.

J Patient Rep Outcomes. 2019 Jun 17;3(1):34. doi: 10.1186/s41687-019-0122-5.


Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial.

Scagliotti GV, Gaafar R, Nowak AK, Nakano T, van Meerbeeck J, Popat S, Vogelzang NJ, Grosso F, Aboelhassan R, Jakopovic M, Ceresoli GL, Taylor P, Orlandi F, Fennell DA, Novello S, Scherpereel A, Kuribayashi K, Cedres S, Sørensen JB, Pavlakis N, Reck M, Velema D, von Wangenheim U, Kim M, Barrueco J, Tsao AS.

Lancet Respir Med. 2019 Jul;7(7):569-580. doi: 10.1016/S2213-2600(19)30139-0. Epub 2019 May 15.


Immune checkpoint inhibition for the treatment of mesothelioma.

Nowak AK, McDonnell A, Cook A.

Expert Opin Biol Ther. 2019 Jul;19(7):697-706. doi: 10.1080/14712598.2019.1606209. Epub 2019 May 2.


Body composition and nutritional status in malignant pleural mesothelioma: implications for activity levels and quality of life.

Jeffery E, Lee YCG, Newton RU, Lyons-Wall P, McVeigh J, Nowak AK, Cheah HM, Nguyen B, Fitzgerald DB, Creaney J, Straker L, Peddle-McIntyre CJ.

Eur J Clin Nutr. 2019 Mar 18. doi: 10.1038/s41430-019-0418-9. [Epub ahead of print]


Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF).

Ha W, Sevim-Nalkiran H, Zaman AM, Matsuda K, Khasraw M, Nowak AK, Chung L, Baxter RC, McDonald KL.

Sci Rep. 2019 Feb 27;9(1):2905. doi: 10.1038/s41598-019-39427-4.


Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study.

Fennell DA, Baas P, Taylor P, Nowak AK, Gilligan D, Nakano T, Pachter JA, Weaver DT, Scherpereel A, Pavlakis N, van Meerbeeck JP, Cedrés S, Nolan L, Kindler H, Aerts JGJV.

J Clin Oncol. 2019 Apr 1;37(10):790-798. doi: 10.1200/JCO.2018.79.0543. Epub 2019 Feb 20.


Patient preferences for adjuvant radiotherapy in early breast cancer are strongly influenced by treatment received through random assignment.

Corica T, Saunders CM, Bulsara MK, Taylor M, Joseph DJ, Nowak AK.

Eur J Cancer Care (Engl). 2019 Mar;28(2):e12985. doi: 10.1111/ecc.12985. Epub 2019 Jan 14.


Tumour associated lymphocytes in the pleural effusions of patients with mesothelioma express high levels of inhibitory receptors.

Chee J, Watson MW, Chopra A, Nguyen B, Cook AM, Creaney J, Lesterhuis WJ, Robinson BW, Lee YCG, Nowak AK, Lake RA, McDonnell AM.

BMC Res Notes. 2018 Dec 5;11(1):864. doi: 10.1186/s13104-018-3953-x.


Prediction modelling using routine clinical parameters to stratify survival in Malignant Pleural Mesothelioma patients undergoing cytoreductive surgery.

Harris EJA, Kao S, McCaughan B, Nakano T, Kondo N, Hyland R, Nowak AK, de Klerk NH, Brims FJH.

J Thorac Oncol. 2019 Feb;14(2):288-293. doi: 10.1016/j.jtho.2018.10.005. Epub 2018 Oct 24.


Combination immune checkpoint blockade as an effective therapy for mesothelioma.

Fear VS, Tilsed C, Chee J, Forbes CA, Casey T, Solin JN, Lansley SM, Joost Lesterhuis W, Dick IM, Nowak AK, Robinson BW, Lake RA, Fisher SA.

Oncoimmunology. 2018 Jul 30;7(10):e1494111. doi: 10.1080/2162402X.2018.1494111. eCollection 2018.


A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma.

Brandes AA, Gil-Gil M, Saran F, Carpentier AF, Nowak AK, Mason W, Zagonel V, Dubois F, Finocchiaro G, Fountzilas G, Cernea DM, Chinot O, Anghel R, Ghiringhelli F, Beauchesne P, Lombardi G, Franceschi E, Makrutzki M, Mpofu C, Urban HJ, Pichler J.

Oncologist. 2019 Apr;24(4):521-528. doi: 10.1634/theoncologist.2018-0290. Epub 2018 Sep 28.


Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation.

Tsao AS, Lindwasser OW, Adjei AA, Adusumilli PS, Beyers ML, Blumenthal GM, Bueno R, Burt BM, Carbone M, Dahlberg SE, de Perrot M, Fennell DA, Friedberg J, Gill RR, Gomez DR, Harpole DH Jr, Hassan R, Hesdorffer M, Hirsch FR, Hmeljak J, Kindler HL, Korn EL, Liu G, Mansfield AS, Nowak AK, Pass HI, Peikert T, Rimner A, Robinson BWS, Rosenzweig KE, Rusch VW, Salgia R, Sepesi B, Simone CB 2nd, Sridhara R, Szlosarek P, Taioli E, Tsao MS, Yang H, Zauderer MG, Malik SM.

J Thorac Oncol. 2018 Nov;13(11):1655-1667. doi: 10.1016/j.jtho.2018.08.2036. Epub 2018 Sep 25.


Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma.

Metaxas Y, Rivalland G, Mauti LA, Klingbiel D, Kao S, Schmid S, Nowak AK, Gautschi O, Bartnick T, Hughes BG, Bouchaab H, Rothschild SI, Pavlakis N, Wolleb S, Petrausch U, O'Byrne K, Froesch P, Löffler-Baumann M, Pratsch-Peter S, Russell P, Mingrone W, Savic S, Thapa B, Früh M, Pless M, von Moos R, John T.

J Thorac Oncol. 2018 Nov;13(11):1784-1791. doi: 10.1016/j.jtho.2018.08.007. Epub 2018 Aug 22.


Revised Modified Response Evaluation Criteria in Solid Tumors for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1).

Armato SG 3rd, Nowak AK.

J Thorac Oncol. 2018 Jul;13(7):1012-1021. doi: 10.1016/j.jtho.2018.04.034. Epub 2018 May 9. Erratum in: J Thorac Oncol. 2019 Mar;14(3):560.


Cosmetic outcome as rated by patients, doctors, nurses and BCCT.core software assessed over 5 years in a subset of patients in the TARGIT-A Trial.

Corica T, Nowak AK, Saunders CM, Bulsara MK, Taylor M, Williams NR, Keshtgar M, Joseph DJ, Vaidya JS.

Radiat Oncol. 2018 Apr 13;13(1):68. doi: 10.1186/s13014-018-0998-x.


Elderly dendritic cells respond to LPS/IFN-γ and CD40L stimulation despite incomplete maturation.

Gardner JK, Cornwall SMJ, Musk AW, Alvarez J, Mamotte CDS, Jackaman C, Nowak AK, Nelson DJ.

PLoS One. 2018 Apr 13;13(4):e0195313. doi: 10.1371/journal.pone.0195313. eCollection 2018.


Vascular targeting of LIGHT normalizes blood vessels in primary brain cancer and induces intratumoural high endothelial venules.

He B, Jabouille A, Steri V, Johansson-Percival A, Michael IP, Kotamraju VR, Junckerstorff R, Nowak AK, Hamzah J, Lee G, Bergers G, Ganss R.

J Pathol. 2018 Jun;245(2):209-221. doi: 10.1002/path.5080. Epub 2018 Apr 20.


Progress in the Management of Malignant Pleural Mesothelioma in 2017.

McCambridge AJ, Napolitano A, Mansfield AS, Fennell DA, Sekido Y, Nowak AK, Reungwetwattana T, Mao W, Pass HI, Carbone M, Yang H, Peikert T.

J Thorac Oncol. 2018 May;13(5):606-623. doi: 10.1016/j.jtho.2018.02.021. Epub 2018 Mar 8. Review.


The Improving Rural Cancer Outcomes Trial: a cluster-randomised controlled trial of a complex intervention to reduce time to diagnosis in rural cancer patients in Western Australia.

Emery JD, Gray V, Walter FM, Cheetham S, Croager EJ, Slevin T, Saunders C, Threlfall T, Auret K, Nowak AK, Geelhoed E, Bulsara M, Holman CDJ.

Br J Cancer. 2018 Mar 20;118(6):e8. doi: 10.1038/bjc.2017.457. Epub 2018 Feb 15.


Comparison between site and central radiological assessments for patients with recurrent glioblastoma on a clinical trial.

Field KM, Fitt G, Rosenthal MA, Simes J, Nowak AK, Barnes EH, Sawkins K, Goh C, Moffat BA, Salinas S, Cher L, Wheeler H, Hovey EJ, Phal PM; CABARET/COGNO Investigators.

Asia Pac J Clin Oncol. 2018 Oct;14(5):e359-e365. doi: 10.1111/ajco.12806. Epub 2017 Nov 8.


A systematic review and meta-analysis of utility estimates in melanoma.

Tran AD, Fogarty G, Nowak AK, Espinoza D, Rowbotham N, Stockler MR, Morton RL.

Br J Dermatol. 2018 Feb;178(2):384-393. doi: 10.1111/bjd.16098. Epub 2018 Jan 17.


A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice.

Aston WJ, Hope DE, Nowak AK, Robinson BW, Lake RA, Lesterhuis WJ.

BMC Cancer. 2017 Oct 16;17(1):684. doi: 10.1186/s12885-017-3677-7.


In Reply.

Klemm E, Nowak AK.

Dtsch Arztebl Int. 2017 Sep 4;114(35-36):604. doi: 10.3238/arztebl.2017.0604a. No abstract available.


The Improving Rural Cancer Outcomes Trial: a cluster-randomised controlled trial of a complex intervention to reduce time to diagnosis in rural cancer patients in Western Australia.

Emery JD, Gray V, Walter FM, Cheetham S, Croager EJ, Slevin T, Saunders C, Threlfall T, Auret K, Nowak AK, Geelhoed E, Bulsara M, Holman CDJ.

Br J Cancer. 2017 Nov 7;117(10):1459-1469. doi: 10.1038/bjc.2017.310. Epub 2017 Sep 19. Erratum in: Br J Cancer. 2018 Feb 15;:.


Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial.

Grosso F, Steele N, Novello S, Nowak AK, Popat S, Greillier L, John T, Leighl NB, Reck M, Taylor P, Planchard D, Sørensen JB, Socinski MA, von Wangenheim U, Loembé AB, Barrueco J, Morsli N, Scagliotti G.

J Clin Oncol. 2017 Nov 1;35(31):3591-3600. doi: 10.1200/JCO.2017.72.9012. Epub 2017 Sep 11.


Do carer's levels of unmet needs change over time when caring for patients diagnosed with high-grade glioma and how are these needs correlated with distress?

Halkett GKB, Lobb EA, Shaw T, Sinclair MM, Miller L, Hovey E, Nowak AK.

Support Care Cancer. 2018 Jan;26(1):275-286. doi: 10.1007/s00520-017-3846-x. Epub 2017 Aug 14.


Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.

van den Bent MJ, Baumert B, Erridge SC, Vogelbaum MA, Nowak AK, Sanson M, Brandes AA, Clement PM, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Brachman DG, Taal W, Rudà R, Weller M, McBain C, Reijneveld J, Enting RH, Weber DC, Lesimple T, Clenton S, Gijtenbeek A, Pascoe S, Herrlinger U, Hau P, Dhermain F, van Heuvel I, Stupp R, Aldape K, Jenkins RB, Dubbink HJ, Dinjens WNM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, Wick W, Kros JM.

Lancet. 2017 Oct 7;390(10103):1645-1653. doi: 10.1016/S0140-6736(17)31442-3. Epub 2017 Aug 8. Erratum in: Lancet. 2017 Oct 7;390(10103):1644.


Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.

Maio M, Scherpereel A, Calabrò L, Aerts J, Cedres Perez S, Bearz A, Nackaerts K, Fennell DA, Kowalski D, Tsao AS, Taylor P, Grosso F, Antonia SJ, Nowak AK, Taboada M, Puglisi M, Stockman PK, Kindler HL.

Lancet Oncol. 2017 Sep;18(9):1261-1273. doi: 10.1016/S1470-2045(17)30446-1. Epub 2017 Jul 17.


LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma.

Scagliotti GV, Gaafar R, Nowak AK, Reck M, Tsao AS, van Meerbeeck J, Vogelzang NJ, Nakano T, von Wangenheim U, Velema D, Morsli N, Popat S.

Clin Lung Cancer. 2017 Sep;18(5):589-593. doi: 10.1016/j.cllc.2017.03.010. Epub 2017 Mar 22.


The role of early magnetic resonance imaging in predicting survival on bevacizumab for recurrent glioblastoma: Results from a prospective clinical trial (CABARET).

Field KM, Phal PM, Fitt G, Goh C, Nowak AK, Rosenthal MA, Simes J, Barnes EH, Sawkins K, Cher LM, Hovey EJ, Wheeler H.

Cancer. 2017 Sep 15;123(18):3576-3582. doi: 10.1002/cncr.30838. Epub 2017 Jul 5.


Corrigendum to "Fertilisers production from ashes after sewage sludge combustion-strategy towards sustainable development" [Environ. Res. 154 (2017) 171-180].

Gorazda K, Tarko B, Wzorek Z, Kominko H, Nowak AK, Kulczycka J, Henclik A, Smol M.

Environ Res. 2017 Oct;158:815. doi: 10.1016/j.envres.2017.06.008. Epub 2017 Jun 26. No abstract available.


Health-related quality of life outcomes from CABARET: a randomized phase 2 trial of carboplatin and bevacizumab in recurrent glioblastoma.

Field KM, King MT, Simes J, Espinoza D, Barnes EH, Sawkins K, Rosenthal MA, Cher L, Hovey E, Wheeler H, Nowak AK.

J Neurooncol. 2017 Jul;133(3):623-631. doi: 10.1007/s11060-017-2479-8. Epub 2017 May 22.


Tracheotomy-Related Deaths.

Klemm E, Nowak AK.

Dtsch Arztebl Int. 2017 Apr 21;114(16):273-279. doi: 10.3238/arztebl.2017.0273. Review.


Feasibility Testing and Refinement of a Supportive Educational Intervention for Carers of Patients with High-Grade Glioma - a Pilot Study.

Halkett GKB, Lobb EA, Miller L, Shaw T, Moorin R, Long A, King A, Clarke J, Fewster S, Nowak AK.

J Cancer Educ. 2018 Oct;33(5):967-975. doi: 10.1007/s13187-017-1175-x.


Tumour-infiltrating regulatory T cell density before neoadjuvant chemoradiotherapy for rectal cancer does not predict treatment response.

McCoy MJ, Hemmings C, Anyaegbu CC, Austin SJ, Lee-Pullen TF, Miller TJ, Bulsara MK, Zeps N, Nowak AK, Lake RA, Platell CF.

Oncotarget. 2017 Mar 21;8(12):19803-19813. doi: 10.18632/oncotarget.15048.


Fertilisers production from ashes after sewage sludge combustion - A strategy towards sustainable development.

Gorazda K, Tarko B, Wzorek Z, Kominko H, Nowak AK, Kulczycka J, Henclik A, Smol M.

Environ Res. 2017 Apr;154:171-180. doi: 10.1016/j.envres.2017.01.002. Epub 2017 Jan 10. Erratum in: Environ Res. 2017 Oct;158:815.


Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity.

Lesterhuis WJ, Bosco A, Millward MJ, Small M, Nowak AK, Lake RA.

Nat Rev Drug Discov. 2017 Apr;16(4):264-272. doi: 10.1038/nrd.2016.233. Epub 2017 Jan 6. Review.


Distress and psychological morbidity do not reduce over time in carers of patients with high-grade glioma.

Halkett GK, Lobb EA, Shaw T, Sinclair MM, Miller L, Hovey E, Nowak AK.

Support Care Cancer. 2017 Mar;25(3):887-893. doi: 10.1007/s00520-016-3478-6. Epub 2016 Nov 14.


Imaging in pleural mesothelioma: A review of the 13th International Conference of the International Mesothelioma Interest Group.

Armato SG 3rd, Blyth KG, Keating JJ, Katz S, Tsim S, Coolen J, Gudmundsson E, Opitz I, Nowak AK.

Lung Cancer. 2016 Nov;101:48-58. doi: 10.1016/j.lungcan.2016.09.003. Epub 2016 Sep 5. Review.


The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma.

Nowak AK, Chansky K, Rice DC, Pass HI, Kindler HL, Shemanski L, Billé A, Rintoul RC, Batirel HF, Thomas CF, Friedberg J, Cedres S, de Perrot M, Rusch VW; Staging and Prognostic Factors Committee, Advisory Boards and Participating Institutions.

J Thorac Oncol. 2016 Dec;11(12):2089-2099. doi: 10.1016/j.jtho.2016.08.147. Epub 2016 Sep 26.


The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma.

Rusch VW, Chansky K, Kindler HL, Nowak AK, Pass HI, Rice DC, Shemanski L, Galateau-Sallé F, McCaughan BC, Nakano T, Ruffini E, van Meerbeeck JP, Yoshimura M; IASLC Staging and Prognostic Factors Committee, advisory boards, and participating institutions.

J Thorac Oncol. 2016 Dec;11(12):2112-2119. doi: 10.1016/j.jtho.2016.09.124. Epub 2016 Sep 28.


Cosmesis and Breast-Related Quality of Life Outcomes After Intraoperative Radiation Therapy for Early Breast Cancer: A Substudy of the TARGIT-A Trial.

Corica T, Nowak AK, Saunders CM, Bulsara M, Taylor M, Vaidya JS, Baum M, Joseph DJ.

Int J Radiat Oncol Biol Phys. 2016 Sep 1;96(1):55-64. doi: 10.1016/j.ijrobp.2016.04.024. Epub 2016 Apr 23.


Human mesothelioma induces defects in dendritic cell numbers and antigen-processing function which predict survival outcomes.

Cornwall SM, Wikstrom M, Musk AW, Alvarez J, Nowak AK, Nelson DJ.

Oncoimmunology. 2015 Aug 31;5(2):e1082028. eCollection 2016 Feb.


PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors.

Meniawy TM, Lake RA, McDonnell AM, Millward MJ, Nowak AK.

Lung Cancer. 2016 Mar;93:9-16. doi: 10.1016/j.lungcan.2015.12.006. Epub 2015 Dec 30.


Malignant pleural mesothelioma: an update on diagnosis and treatment options.

Kondola S, Manners D, Nowak AK.

Ther Adv Respir Dis. 2016 Jun;10(3):275-88. doi: 10.1177/1753465816628800. Epub 2016 Feb 12. Review.


Asbestos exposure: challenges for Australian clinicians.

Musk AW, de Klerk NH, Nowak AK.

Med J Aust. 2016 Feb 1;204(2):48-9. No abstract available.


Supplemental Content

Loading ...
Support Center